Current Appointments & Affiliations
Associate Professor of Medicine
·
2024 - Present
Medicine, Hematologic Malignancies and Cellular Therapy,
Medicine
Member of the Duke Cancer Institute
·
2016 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA.
Journal Article J Clin Oncol · March 2025 Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Up ... Full text Link to item CiteA phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies.
Journal Article Blood Adv · February 25, 2025 The antiapoptotic protein, myeloid cell leukemia-1 (Mcl-1), contributes to the pathophysiology of acute myeloid leukemia (AML) and certain B-cell malignancies. Tumor dependence on Mcl-1 is associated with resistance to venetoclax. Voruciclib, an oral cycli ... Full text Link to item CiteOutcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL.
Journal Article Blood Cancer J · February 20, 2025 Full text Link to item CiteRecent Grants
A Phase 1 Study of ABBV-453 in Adult Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2025 - 2030Short Title Phase 3 Sonrotoclax + Zanubrutinib compared with Ven + Obinutuzumab in Patients untreated CLL
Clinical TrialPrincipal Investigator · Awarded by BeiGene USA, Inc. · 2024 - 2029A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton?s Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies
Clinical TrialPrincipal Investigator · Awarded by Nurix Therapeutics, Inc. · 2024 - 2029View All Grants
Education, Training & Certifications
Duke University, School of Medicine ·
2007
M.D.